Insights Into Rural Chemotherapy Usage for Muscle-Invasive Bladder Cancer: An Australian Multi-Site Institution Perspective.
作者信息
Huynh Tran Ngoc An, Arulshankar Samiha, Wei Xinyi, Lim Kylie Yen-Yi, Huang James, Rajarubendra Nieroshan, Chu Kevin, Harper Matthew, Donnellan Scott, Ranasinghe Weranja
机构信息
Department of Urology, Casey Hospital, Monash Health, Victoria, Australia.
School of Medicine, Nursing and Health Science, Monash University, Victoria, Australia.
出版信息
ANZ J Surg. 2025 Jul-Aug;95(7-8):1296-1298. doi: 10.1111/ans.70175. Epub 2025 May 22.
Abstract
摘要
相似文献
1
Insights Into Rural Chemotherapy Usage for Muscle-Invasive Bladder Cancer: An Australian Multi-Site Institution Perspective.深入了解农村地区肌肉浸润性膀胱癌的化疗使用情况：澳大利亚多机构视角
ANZ J Surg. 2025 Jul-Aug;95(7-8):1296-1298. doi: 10.1111/ans.70175. Epub 2025 May 22.
2
A Retrospective Analysis of the Effect on Survival of Time from Diagnosis to Neoadjuvant Chemotherapy to Cystectomy for Muscle Invasive Bladder Cancer.从诊断到新辅助化疗再到根治性膀胱切除术的时间对肌层浸润性膀胱癌患者生存影响的回顾性分析
J Urol. 2016 Apr;195(4 Pt 1):880-5. doi: 10.1016/j.juro.2015.11.024. Epub 2015 Nov 18.
3
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer.肌层浸润性膀胱癌新辅助化疗和辅助化疗的系统评价。
Eur Urol. 2012 Sep;62(3):523-33. doi: 10.1016/j.eururo.2012.05.048. Epub 2012 Jun 1.
4
Potential therapeutic effects of adjuvant chemotherapy after neoadjuvant chemotherapy for locally advanced muscle-invasive bladder cancer.新辅助化疗后辅助化疗治疗局部晚期肌层浸润性膀胱癌的潜在疗效。
Jpn J Clin Oncol. 2022 Apr 6;52(4):388-396. doi: 10.1093/jjco/hyab210.
5
Does Neoadjuvant Chemotherapy Followed by Radical Cystectomy Improve the Survival of Muscle-Invasive Bladder Cancer in Real-World Clinical Practice?在真实世界临床实践中，新辅助化疗后行根治性膀胱切除术能否提高肌层浸润性膀胱癌的生存率？
Int J Urol. 2025 Jul;32(7):830-838. doi: 10.1111/iju.70064. Epub 2025 Apr 11.
6
Neoadjuvant versus Adjuvant Chemotherapy in Patients with Resectable Muscle-Invasive Bladder Cancer.可切除的肌层浸润性膀胱癌患者的新辅助化疗与辅助化疗。
Asian Pac J Cancer Prev. 2022 Nov 1;23(11):3641-3647. doi: 10.31557/APJCP.2022.23.11.3641.
7
Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer.新辅助与辅助吉西他滨联合顺铂化疗治疗肌层浸润性膀胱癌的比较
Asia Pac J Clin Oncol. 2013 Dec;9(4):310-7. doi: 10.1111/ajco.12017. Epub 2012 Nov 6.
8
The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy.对于不符合基于顺铂化疗条件的肌层浸润性膀胱癌患者，新辅助吉西他滨联合卡铂治疗后立即进行根治性膀胱切除术的效用。
Int J Clin Oncol. 2017 Feb;22(1):159-165. doi: 10.1007/s10147-016-1029-2. Epub 2016 Aug 17.
9
Perioperative chemotherapy and immunotherapy to optimize cystectomy outcomes in the curative intent of non-metastatic muscle-invasive bladder cancer: A systematic review and meta-analysis.根治性意图下非转移性肌层浸润性膀胱癌行膀胱切除术的围手术期化疗和免疫治疗以优化结局：系统评价和荟萃分析。
Fr J Urol. 2024 Sep;34(9):102704. doi: 10.1016/j.fjurol.2024.102704. Epub 2024 Jul 24.
10
A systematic overview of chemotherapy effects in urothelial bladder cancer.尿路上皮膀胱癌化疗效果的系统综述。
Acta Oncol. 2001;40(2-3):371-90. doi: 10.1080/02841860151116466.
本文引用的文献
1
Improving quality of care by standardising patient data collection in electronic medical records in an oncology department in Spain.提高西班牙肿瘤科电子病历中患者数据采集的标准化水平，改善医疗服务质量。
BMJ Open Qual. 2024 Jun 19;13(2):e002732. doi: 10.1136/bmjoq-2023-002732.
2
Lessons from a population-based bladder cancer registry: exploring why survival is not improving.基于人群的膀胱癌登记处的经验教训：探索为何生存率没有提高。
BJU Int. 2024 Jun;133(6):699-708. doi: 10.1111/bju.16286. Epub 2024 Feb 26.
3
Patterns of chemotherapy use in muscle-invasive bladder cancer in a tertiary centre.三级医疗中心肌层浸润性膀胱癌的化疗使用模式
Bladder (San Franc). 2023 Dec 11;10:e21200013. doi: 10.14440/bladder.2023.872. eCollection 2023.
4
Epidemiology of Bladder Cancer in 2023: A Systematic Review of Risk Factors.2023 年膀胱癌的流行病学：危险因素的系统评价。
Eur Urol. 2023 Aug;84(2):176-190. doi: 10.1016/j.eururo.2023.03.029. Epub 2023 May 16.
5
Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis of Individual Participant Data from Randomised Controlled Trials.辅助化疗治疗肌层浸润性膀胱癌：随机对照试验个体参与者数据的系统评价和荟萃分析。
Eur Urol. 2022 Jan;81(1):50-61. doi: 10.1016/j.eururo.2021.09.028. Epub 2021 Nov 19.
6
Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline.非转移性肌肉浸润性膀胱癌治疗：AUA/ASCO/ASTRO/SUO 指南。
J Urol. 2017 Sep;198(3):552-559. doi: 10.1016/j.juro.2017.04.086. Epub 2017 Apr 26.
7
Cancer health inequality persists in regional and remote Australia.澳大利亚偏远地区的癌症健康不平等现象依然存在。
Med J Aust. 2014 Oct 20;201(8):445-6. doi: 10.5694/mja14.01217.
8
The shortage of medical oncologists: the Australian Medical Oncologist Workforce Study.肿瘤内科医生短缺：澳大利亚肿瘤内科医生劳动力研究。
Med J Aust. 2012 Jan 16;196(1):58-61. doi: 10.5694/mja11.10363.
9
Management of muscle-invasive bladder cancer in Victoria, 1990-1995.1990 - 1995年维多利亚州肌层浸润性膀胱癌的管理
ANZ J Surg. 2006 Mar;76(3):113-9. doi: 10.1111/j.1445-2197.2006.03665.x.
Zotero 插件